NEWS AND DEVELOPMENT

  • Interim Phase IIb Data Show Promising Reduction In Risk of Recurrence and a Well-Tolerated Safety Profile in Patients with Resected, High-Risk Melanoma
    More
  • TLPLDC Demonstrates Encouraging Clinical Activity and Favorable Safety and Tolerability Profile in Combination with FDA-Approved Systemic Therapies
    More
  • Elios Therapeutics, LLC recently received FDA approval of its Investigational New Drug (IND) application and its randomized phase IIb trial planned to enroll 120 stage III and IV (resected) melanoma patients to assess the ability of a personalized vaccine to prevent recurrence.
    More
  • Vaccine for Cancer Comes Closer to Fruition as Immunotherapy Pioneer Joins Orbis Health Solutions
    More
  • Buddy Long, president of Perseus PCI, the advanced cancer treatment center headquartered in the Cayman Islands, has announced the appointment of Dr. Sook Yin MD as treating physician and clinic director at the company’s Cayman Islands clinic.
    More

Immunotherapy Treatment for Cancer and Beyond

Revolutionizing Science. Transforming Life

Orbis Health Solutions is a privately-held biotechnology company based in Greenville, South Carolina seeking to improve the lives of people with immune-mediated conditions by developing transformative medicines that target the body’s immune system and ignite its natural ability to repair and restore health.

Founded in 2009, Orbis was built upon a bold vision to eradicate cancer and immune-mediated conditions through the development of breakthrough immunotherapies that improve standards of care. Our mission is to develop next-generation immunotherapies that will make a meaningful difference in the lives of patients, caregivers and physicians.

Founded on Breakthrough Science

Orbis was founded by Dr. Thomas Wagner, an internationally-renowned, award-winning pioneer of biomedical research and molecular biology. Dr. Wagner’s personal and scientific journey led him to develop and patent transgenic technology which has revolutionized the way we research cancer today. He was also among the first to develop methods of cell-based therapies, and for the past two decades, Dr. Wagner’s research has focused exclusively on the application of modern molecular and cellular biology to the development of new therapies for the treatment of cancer.

Doctor Thomas Wagner

Renowned cancer researcher Dr. Thomas Wagner, creator of the Perseus PCI Vaccine

Dr. Wagner has served as a scientific advisor to the World Health Organ-ization, to the U.S. Congress, and to the White House under former President Ronald Reagan. Based on over 50 years of Dr. Wagner’s breakthrough scientific research and discovery, Orbis’ cutting-edge technology can deliver therapeutic opportunities for currently intractable diseases.

As one of South Carolina’s premier scientific research centers, Orbis has an unparalleled track record when it comes to clinical impact and excellence. Our researchers have collaborated to turn radical ideas into life-changing realities, from creating personalized therapeutic cancer vaccines to an immunology-based serum that regenerates and renews damaged skin.

We believe our unique approach to research leads to new, creative approaches that overcome barriers and improve clinical outcomes. This combined with our adaptiveness and resourcefulness make Orbis well-suited to tackle and identify innovative and revolutionary solutions to some of medicine’s toughest challenges.

Harnessing the Synergistic Power of the Immune System

Cancer is one of the deadliest diseases that arises from our own cells. This creates a very confusing situation for our immune system. To launch an immune response, the body has to be able to tell the difference between cells that are “self” and “non-self.”

One reason cancer is so difficult to treat is that it avoids detection because the immune system thinks it is “self.” Without a way for the immune system to tell the difference between a healthy cell and a cancer cell, there is little the body can do to prevent cancer from taking over.

Orbis’ technology uses a proprietary particle delivery system that helps the body’s immune system recognize foreign invaders as “non-self” allowing it to seek out and to destroy cancer and other immune-mediated conditions.

Orbis has developed a pipeline of immunotherapy-based products that are designed to harness the potent role of the body’s innate immune system to repair and to restore health. Each of our product candidates have their own distinct clinical characteristics, target indications, commercialization potential, and unique partnering opportunities.